Clinical Trial Update: A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps [Phase 3]

View source ↗

Summary

A Phase 3 study is evaluating itepekimab, an anti-IL-33 monoclonal antibody, for inadequately controlled chronic rhinosinusitis with nasal polyps. The trial is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rhinosinusitis with Nasal Polyps

Drugs mentioned

• itepekimab (itepekimab)

Snippet

Sponsor: Sanofi | Conditions: Chronic Rhinosinusitis With Nasal Polyps | Phase 3 | Status: RECRUITING